Vivos Therapeutics Files S-1 for Potential Offering

TL;DR

Vivos Therapeutics just filed an S-1, looks like they're prepping for a public stock offering.

AI Summary

Vivos Therapeutics, Inc. filed an S-1 registration statement on January 21, 2025, for an unspecified number of shares. The company, formerly Vivos BioTechnologies, Inc., is incorporated in Delaware and headquartered in Littleton, Colorado. The filing indicates a potential offering of securities, though specific details on the number of shares or price are not yet disclosed in this initial document.

Why It Matters

This S-1 filing signals Vivos Therapeutics' intention to raise capital through a public offering, which could fund its growth and product development in the medical device sector.

Risk Assessment

Risk Level: medium — As an S-1 filing, it represents a company seeking to go public or raise additional capital, which inherently carries market and execution risks.

Key Numbers

• 20250121 — Filing Date (Indicates the date the S-1 was submitted to the SEC.)
• 1231 — Fiscal Year End (Marks the end of the company's financial reporting year.)

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Registrant
• Vivos BioTechnologies, Inc. (company) — Former company name
• R. Kirk Huntsman (person) — Chairman of the Board and Chief Executive Officer
• Barry I. Grossman, Esq. (person) — Legal counsel
• 3841 (dollar_amount) — Standard Industrial Classification Code for Surgical & Medical Instruments & Apparatus
• 813224056 (dollar_amount) — IRS Employer Identification No.
• 333-284399 (dollar_amount) — SEC File Number
• 25543802 (dollar_amount) — Film Number

FAQ

Key Financial Figures

• $0.0001 — 4,332 shares of Common Stock, par value $0.0001 per share (“Common Stock”),
• $5.74 — Common Stock as reported on Nasdaq was $5.74 per share. We are an “emerging
• $149.6 billion — OSA has an annual societal cost of over $149.6 billion. According to the study “ Global

Filing Documents

• forms-1.htm (S-1) — 1084KB
• ex5-1.htm (EX-5.1) — 19KB
• ex21-1.htm (EX-21.1) — 9KB
• ex23-1.htm (EX-23.1) — 1KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107.htm (EX-FILING FEES) — 22KB
• forms-1_001.jpg (GRAPHIC) — 7KB
• ex23-1_001.jpg (GRAPHIC) — 162KB
• ex23-2_001.jpg (GRAPHIC) — 27KB
• ex23-2_002.jpg (GRAPHIC) — 11KB
• 0001493152-25-003115.txt ( ) — 1424KB

Risk Factors

Risk Factors 16 Cautionary Note Regarding Forward-Looking Statements 16

Use of Proceeds

Use of Proceeds 18 Dividend Policy 18 Determination of Offering Price 18 Market for Common Equity and Related Stockholder Matters 18 Management’s Discussion and Analysis of Financial Condition and Results of Operations 18

Business

Business 19 Management 48

Executive Compensation

Executive Compensation 48 Certain Relationships and Related Party Transactions 60 Principal Stockholders 61

Description of Capital Stock

Description of Capital Stock 62 Selling Stockholders 69 Plan of Distribution 72 Legal Matters 73 Experts 73 Where You Can Find More Information 73 Material Changes 74 Incorporation of Certain Information by Reference 74 Please read this prospectus carefully. It describes our business, our financial condition and our results of operations. We have prepared this prospectus so that you will have the information necessary to make an informed investment decision. You should rely only on the information contained or incorporated by reference in this prospectus. We and the selling stockholders have not authorized anyone to provide you with any information or to make any representations about us, the securities being offered pursuant to this prospectus or any other matter discussed in this prospectus, other than the information and representations contained or incorporated by reference in this prospectus. If any other information or representation is given or made, such information or representation may not be relied upon as having been authorized by us. The information contained or incorporated by reference in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our Common Stock. Neither the delivery of this prospectus nor any distribution of securities in accordance with this prospectus shall, under any circumstances, imply that there has been no change in our affairs since the date of this prospectus. This prospectus will be updated and made available for delivery to the extent required by the federal securities laws. We are responsible for the disclosure in this prospectus. However, this prospectus includes industry data that we obtained from internal surveys, market research, publicly available information and industry publications. The market research, publicly available information and industry publications that we use generally state that the informatio

View Full Filing

View this S-1 filing on SEC EDGAR